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Summary
Background Evidence on the effectiveness of opioid agonist treatment (OAT) in reducing crime is mixed. We aimed to 
assess the effect of OAT on crime in terms of delaying time to first charge and reducing overall charge rates, as well 
as the relationship between OAT retention and overall charge rates.
Methods We did a retrospective cohort study of opioid-dependent people who entered OAT for the first time between 
Jan 1, 2004, and Dec 30, 2010, in New South Wales (NSW), Australia. We used three linked NSW and national 
administrative datasets. Data on OAT were obtained from the Pharmaceutical Drugs of Addiction System, data on 
charges were obtained from the Reoffending Database, and data on mortality were obtained from the National Death 
Index. The cohort was followed up until Dec 31, 2011. Time-dependent OAT exposure was modelled using Cox 
proportional hazards models (time to first charge) and Andersen-Gill intensity models (total charge-days). Retention 
in OAT was modelled using two features of treatment engagement, number of OAT episodes and proportion of 
follow-up time in OAT (presented in quartile groupings: lowest, low-mid, low-high, highest) using zero-inflated 
negative binomial regression (total charges). All models were adjusted for sociodemographic, criminographic, and 
treatment-related variables.
Findings 10 744 new OAT entrants were included in the study. 5751 (53·5%) people were charged with an offence. In 
adjusted analyses, OAT was associated with an initial benefit in delaying the time to first charge (hazard ratio 0·43, 
95% CI 0·33–0·55) and reducing total charge-days (0·39, 95% CI 0·30–0·52); however, these protective effects 
reduced over time. Total charge rates were higher as the number of OAT episodes increased (incident rate ratio [IRR] 
1·13, 95% CI 1·11–1·15), and when relatively lower proportions of time were spent in OAT (IRR among the lowest 
three quartiles ranged from 1·11 [95% CI 1·02–1·21] to 1·22 [95% CI 1·12–1·33]).
Interpretation OAT was associated with a reduction in overall charge rates and was more protective as treatment 
engagement increased. Maximising treatment retention is crucial to achieving long-term health and social benefits 
of OAT.
Funding Australian National Health and Medical Research Council, Australian Institute of Criminology, National 
Institute on Drug Abuse, Australian Government Department of Health, UNSW Sydney.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 
license.
Introduction
Opioid dependence is a chronic disorder with many 
health and social consequences.1,2 In addition to the 
negative effects on morbidity and mortality,1 studies 
show a strong link between illicit opioid use and criminal 
activity.3–5 The onset of opioid use increases offending,6 
and people who are opioid dependent are often in 
frequent contact with the criminal justice system, in 
terms of increased rates of offending, largely because of 
acquisitive crimes, and imprisonment.3,7 The corres­
ponding societal costs and economic burden associated 
with crime arising from opioid dependence are especially 
pronounced.8,9
Opioid agonist treatment (OAT; methadone and 
buprenorphine) is one of the most widely used treatments 
for opioid dependence worldwide. Regarded as essential 
medicines by WHO, strong evidence exists that methadone 
and buprenorphine are effective in reducing heroin use,10 
injecting risk,11 HIV and hepatitis C incidence,12 and 
mortality.1,13 In addition to these benefits, there is ongoing 
interest in examining the effectiveness of OAT in reducing 
contact with the criminal justice system to reduce the 
economic burden associated with opioid dependence.
Investigating the relationship between OAT and crime 
is complex, with randomised controlled trials14–16 and 
observational studies17–21 reporting varying effects depend­
ing on how treatment exposure has been assessed, and 
across treatment programmes and settings. For example, 
in a population­based study in Norway, reduct ions in 
crime were found in the period immediately before entry 
(or re­entry) into OAT, with increases in crime in the 
months before treatment interruption.17 Furthermore, 
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continuous treatment was associated with the greatest 
crime reductions.18 Studies in Australia21 and Canada20 
have documented lower offending rates during periods in 
which individuals were receiving methadone treatment 
than during periods without treatment. In the UK, crime 
reductions have been observed only during periods of 
continuous treatment with methadone, with non­
continuous treatment having little benefit in reducing 
crime.19
Although these studies have documented important 
findings regarding the complexity of reducing crime in 
individuals in OAT, no study has comprehensively 
examined the effect of various OAT exposures on crime 
in a whole population and the effect of retention in OAT 
on crime is poorly understood. Using a population­based 
cohort of new OAT treatment entrants (including 
methadone and buprenorphine), we aimed to examine 
the effectiveness of OAT in reducing charge rates among 
opioid­dependent people. The specific objectives were to 
examine the effectiveness of OAT in delaying the time to 
first charge after entry into treatment, relative to time 
not spent in OAT; examine the effectiveness of OAT in 
reducing overall charge rates relative to time not spent in 
OAT; and examine the relationship between retention 
in OAT and reductions in overall charge rates.
Methods
Study design and setting
We did a retrospective population­based cohort study of 
opioid­dependent people who entered OAT for the first 
time between Jan 1, 2004, and Dec 30, 2010, in New South 
Wales (NSW), Australia. In Australia, treatment for 
opioid dependence is primarily focused on the provision 
of pharmacotherapy in the form of OAT. OAT is avail able 
from community pharmacies, public and private clinics, 
and correctional facilities; additional psychological 
Research in context
Evidence before this study
We searched PubMed from inception up to Dec 14, 2018, for 
studies examining the effect of opioid agonist treatment (OAT) 
on criminal activity among opioid-dependent people using 
longitudinal study designs that were able to gather information 
on exposure to OAT and on offending or criminal behaviour in a 
continuous manner across time. We used the Medical Subject 
Headings terms “opiate substitution treatment or OST” AND 
“crime OR crim*” and limited to humans. We also reviewed 
Cochrane reviews of OAT outcomes in randomised controlled 
trials (RCTs).
The three Cochrane reviews of RCTs varied in their conclusions. 
Those that used dichotomous measures of any offending 
during the trial found no significant effects, whereas the review 
that used a continuous measure of criminal activity found 
reductions during treatment.
A more precise method of assessing criminal behaviour is 
through daily assessment, as is the case for exposure to OAT. 
Police registry data afford this possibility, although such data 
are subject to the limitations that they only include crimes for 
which a person received a charge from the police (a subset of all 
offending behaviour). We obtained 267 results in the PubMed 
search, of which 16 studies were eligible for inclusion.
Several smaller linkage studies focusing on opioid-dependent 
people in prison suggested that being released from prison 
while on OAT reduces the risk of reincarceration; however, not 
all studies have reported this finding. Those who have been 
incarcerated could represent a subgroup of opioid-dependent 
people who have already become more heavily involved in 
criminal activity than have those who have not been 
incarcerated.
In the community-based studies of opioid-dependent people 
that used linked data, a range of methodological approaches 
were used to assess potential effects upon criminal behaviour. 
Most used a pre-post study design, in which offending rates 
before and after first entry into OAT were compared. Some 
studies additionally compared criminal activity after leaving 
OAT with that during receipt of OAT. None examined different 
patterns of engagement with treatment (considering length 
and number of episodes, indicative of extent and rapidity of 
cycling in and out of treatment), and none examined time to 
first offence after first treatment initiation and overall 
offending, considering a range of treatment characteristics.
Added value of this study
Our study represents the most detailed and well-powered study 
to date of the potential effects of OAT upon police charges 
during specific periods in and out of treatment for opioid 
dependence. Just over half of all people who entered OAT had a 
criminal charge at some point during follow-up. OAT had an 
initial beneficial effect in both delaying the time to first charge 
and reducing the overall number of charge-days, although this 
protective effect decayed over time. Being in OAT was also 
found to significantly reduce the total number of charges and 
was more protective as treatment engagement increased—
ie, people whose pattern of OAT involved multiple interrupted 
treatment episodes and a relatively lower proportion of time 
spent in OAT were charged with more offences.
Implications of all the available evidence
Our findings suggest that it is not only time spent in OAT that 
is related to offending, but also the continuous time spent in 
OAT. People who cycle in and out of treatment appear to be at 
higher risk of offending. This finding might explain the 
somewhat inconsistent findings across different measures of 
offending and of treatment exposure that have been found in 
previous studies, which have not tended to measure 
treatment engagement in the detailed manner that was 
undertaken in this study. Cross-cohort analyses to corroborate 
our findings are warranted.
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services are generally limited to clinical and correctional 
settings. There is no charge for treatment in public 
clinics or correctional facilities; however, private clinics 
and community pharmacies charge their clients daily 
dispensing fees (typically AUS$5–8 per day). NSW is 
the most populous state of Australia (accounting for 
approximately 32% of the total population) and 40% of 
OAT recipients in Australia are estimated to reside 
in NSW.22
Ethics approval was obtained from the ethics 
committees of the NSW Aboriginal Health and Medical 
Research Council, University of New South Wales, NSW 
Health’s Population and Health Services Research 
Ethics Committee, the Australian Institute of Health 
and Welfare, the Alfred Hospital (Victoria), Corrective 
Services NSW, Justice Health and Forensic Mental 
Health Network (NSW Health), and the Department of 
Justice (Victoria).
Data sources
We used three linked NSW and national administrative 
datasets that record information on OAT episodes, 
involvement in the criminal justice system (charges and 
incarcerations), and death notifications. Records were 
linked probabilistically by external agencies using each 
individual’s full name, date of birth, sex, and date and 
state of last known contact and then de­identified.
Data on OAT (2004–11) were obtained from the 
Pharmaceutical Drugs of Addiction System (PHDAS). 
The PHDAS is a database of all recipients of methadone 
and buprenorphine or buprenorphine­naloxone in NSW. 
The database records each patient’s full name, date of 
birth, sex, and postcode of residence. Because proof of 
identity must be shown to the prescribing doctor before a 
prescription can be issued, the name and date of birth 
variables are of high accuracy in this dataset. The PHDAS 
records patient admissions and exits from the treatment 
programme and the medication dispensed.
Data on charges (2000–11) were obtained from the 
Reoffending Database (ROD). The ROD is maintained by 
the NSW Bureau of Crime Statistics and Research and 
contains records of all finalised court appearances 
(ie, court matters that are completed and have an out­
come) in NSW. These appearances relate to a charge 
against an individual and include data on the date of 
appearance, date of offence, type of offence, and charge 
outcome (ie, proven or not). A proven charge is one in 
which the defendant pleaded guilty or was found guilty 
by a magistrate or jury. Validation studies have deemed 
that the internal matching process of records for 
individuals in the ROD has a specificity of 99·9% and 
sensitivity of 93·8%.25 All analyses are based on the 
offence date and include only proven charges. The ROD 
also contains incarceration records (2000–11) from the 
NSW Department of Corrective Services. These data 
include the dates of entry and exit for each prison 
episode.
Data on mortality (2000–11) were obtained from the 
National Death Index (NDI). The NDI is a database held by 
the Australian Institute of Health and Welfare that contains 
data on deaths from each Australian State or Territory. 
Dates of death were used for non­informative censoring.
Observation commenced on the date exactly 4 years 
before first entering OAT and ended on Dec 31, 2011, or 
the date of death, whichever was earlier. Charge rates 
could therefore be compared over a minimum 1­year 
period after initial entry into OAT (except in the case of 
death), while establishing a baseline charge history in the 
4 years immediately before OAT entry (representing the 
average time lag before an individual enters treatment 
after becoming opioid dependent in NSW23). Ongoing 
opioid dependence was also assumed following first 
entry into OAT, given that opioid dependence is a chronic 
relapsing disorder with low remission rates.2,24
Statistical analysis
OAT exposure was examined in a time­dependent 
manner, accounting for each day a person was either in or 
out of treatment during the observation period. All 
models were adjusted for a range of sociodemographic 
(age, sex, Indigeneity), criminographic (time in prison 
during follow­up, and number of charges and prison 
episodes in the 4 years before OAT entry), and treatment­
related variables (year of first OAT entry). Sensitivity 
analyses were done truncating the follow­up period to 
June 30, 2011, to examine the potential effect of not 
capturing offences that occurred on or before Dec 31, 2011, 
but were finalised after this date.
We used Cox proportional hazards regression to 
investi gate the association between OAT exposure and 
the time to first charge following each person’s first entry 
into OAT. The effect of OAT on reducing overall charges, 
taking into account recurrent charges, was investigated 
using an Andersen­Gill intensity model.26 Because people 
could have multiple charges on the same day, the out­
come of interest was charge­days. The resulting hazard 
ratio (HR) represents the proportionate change in the 
charge rate due to a change in treatment.
The proportional hazards assumption in the Cox and 
Andersen­Gill models were assessed visually with scaled 
Schoenfeld residuals plots and statistically with cor­
relation tests of the Schoenfeld residuals with time. These 
investigations suggested that the HR of OAT versus not in 
OAT was time­dependent and time­varying models were 
considered. Parameter coefficients were exponentiated 
and were reported as HRs, and robust standard errors in 
the Andersen­Gill models allowed for dependency of 
multiple events within the same individual. Significance 
tests were done using two­sided tests at a level of 0·05.
The effect of OAT retention on the total number of 
charges during follow­up was investigated using zero­
inflated negative binomial regression because of zero­
inflation and overdispersion in the charge data. The 
appropriateness of the model was compared with 
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negative binomial regression using the Vuong test and 
zero­inflated Poisson regression using likelihood­ratio 
tests.27 Parameter coefficients were reported as odds 
ratios (ORs) for the no charge component of the model, 
and incidence rate ratios (IRRs) for the number of 
charges component.
OAT retention was examined using two indicators of 
treatment engagement: total number of OAT episodes and 
proportion of follow­up time spent in OAT. A continuous 
treatment episode was defined as an episode with a break 
of 6 days or fewer between a treatment exit date and date of 
re­entry.28 The proportion of follow­up time each individual 
spent in OAT was categorised into four groups (lowest, 
low­mid, high­mid, and highest), with the quartile cutoff 
points determined using data on individuals with the same 
number of treatment episodes. Charges were categorised 
as occurring in or out of OAT on the basis of whether OAT 
was received on the date of the offence, irrespective of 
whether it occurred during a short (ie, ≤6 day) treatment 
break. All analyses were done using SAS (version 9.4).
Role of the funding source
The funders of the study had no role in study design, 
data analysis, data interpretation, or writing of the report. 
All authors had full access to all study data and had final 
responsibility for the decision to submit for publication.
Results
Of the 10 744 individuals in the cohort, most were men 
(7607 [70·8%]) and non­Indigenous (8277 [77·0%]; 
appendix p 4). The median age at OAT entry was 29·1 years 
(IQR 24·3–36·2). In the 4 years before OAT entry, 6459 
(60·1%) individuals were charged with at least one offence 
and 3900 (36·3%) were incarcerated. The median length 
of follow­up was 4·4 years, ranging from 3 days to 8 years, 
with 379 (3·5%) recorded deaths. Approximately half of 
the cohort (49·4%) were not in treatment 1 year after OAT 
initiation (appendix p 6). 5751 (53·5%) people were 
charged with at least one offence during follow­up, with a 
cumulative total of 39 794 charges and 23 869 charge­days 
across the cohort (appendix p 5).
Table 1 presents the results examining the effectiveness 
of OAT in delaying the time to first charge. In the 
unadjusted analysis, OAT was found to delay the time to 
first charge (table 1 [model 1]). After adjusting for sex and 
age, OAT showed an initial benefit in delaying the time to 
first charge; however, this effect was not consistent over 
time (table 1 [model 2]). Similar results for OAT were 
observed in the model adjusting for all sociodemographic 
Figure 1: Simple 30-day moving average daily charge rate for individuals in 
and out of OAT
For any given day, the daily charge rate was calculated as the number of charges 
divided by the number of people in or out of OAT (multiplied by 100). Simple 
30-day moving average on any given day refers to the arithmetic mean of charge 
rates from the past 30 days. OAT=opioid agonist treatment.
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Model 1 Model 2 Model 3
OAT*
In OAT 0·82 (0·78–0·87) 0·36 (0·28–0·46) 0·43 (0·33–0·55)
In OAT x ln(time since OAT 
initiation)*
NA 1·17 (1·12–1·22) 1·15 (1·10–1·20)
Not in OAT (ref) 1 1 1
Sex
Male 1·36 (1·28–1·44) 1·40 (1·32–1·49) 1·20 (1·13–1·27)
Female (ref) 1 1 1
Indigenous
Yes 1·91 (1·80–2·02) NA 1·37 (1·29–1·46)
No (ref) 1 NA 1
Age at OAT initiation
<25 years 2·08 (1·93–2·23) 2·09 (1·95–2·25) 1·57 (1·46–1·69)
25–29 years 1·62 (1·50–1·75) 1·62 (1·50–1·75) 1·40 (1·30–1·52)
30–34 years 1·45 (1·34–1·58) 1·46 (1·34–1·59) 1·31 (1·20–1·42)
≥35 years (ref) 1 1 1
Year of OAT initiation
2004–05 (ref) 1 NA 1
2006–07 0·94 (0·89–1·01) NA 0·95 (0·89–1·02)
2008–09 0·81 (0·75–0·86) NA 0·85 (0·79–0·91)
2010–11 0·61 (0·55–0·67) NA 0·65 (0·59–0·72)
Number of charges in the 4 years before OAT initiation
0 (ref) 1 NA 1
1–4 2·29 (2·13–2·46) NA 2·14 (1·99–2·31)
5–14 3·58 (3·34–3·84) NA 3·13 (2·86–3·42)
≥15 4·51 (4·14–4·92) NA 4·02 (3·58–4·52)
In prison*
Yes 0·56 (0·50–0·62) NA 0·23 (0·21–0·26)
No (ref) 1 NA 1
Number of prison episodes in the 4 years before OAT initiation
0 (ref) 1 NA 1
1–5 1·69 (1·57–1·82) NA 1·07 (0·98–1·17)
6–10 2·29 (2·13–2·46) NA 1·31 (1·20–1·44)
≥11 2·98 (2·75–3·22) NA 1·56 (1·40–1·74)
Data include 10 744 people and 5751 charge-days. Data are HR (95% CI). Results are from Cox proportional hazards 
regressions. Model 1 used bivariate models. Model 2 included age, sex, treatment, and a time-dependent coefficient 
for “in OAT”. Model 3 was further adjusted for all sociodemographic and criminographic variables. OAT initiation refers 
to first entry into OAT. OAT=opioid agonist treatment. NA=not applicable. HR=hazard ratio. *Time-dependent 
variable.
Table 1: Association between time spent in OAT and hazard of first charge
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Number of 
charges
Person-years Charges per 
100 person-years 
(95% CI)
6-month step-function for OAT Continuous time-dependent 
coefficient for OAT
Model 1 Model 2 Model 3 Model 4 Model 5
OAT*
Not in OAT (ref) 13 582 25 304·9 53·7 
(52·8–54·6)
1 1 1 1 1
In OAT 10 287 22 465·0 45·8 
(44·9–46·7)
0·79 (0·75–0·83) ·· ·· 0·28 
(0·22–0·36)
0·39 
(0·30–0·52)
In OAT x ln(time since OAT 
initiation)*
·· ·· ·· ·· NA NA 1·18 
(1·14–1·23)
1·12 
(1·07–1·17)
Years since OAT initiation
0–0·5 ·· ·· ·· ·· 0·63 
(0·57–0·70)
0·69 
(0·62–0·76)
·· ··
>0·5–1·0 ·· ·· ·· ·· 0·67 
(0·60–0·73)
0·71 
(0·65–0·78)
·· ··
>1·0–1·5 ·· ·· ·· ·· 0·78 
(0·71–0·87)
0·82 
(0·74–0·90)
·· ··
>1·5–2·0 ·· ·· ·· ·· 0·76 
(0·68–0·86)
0·78 
(0·70–0·88)
·· ··
>2·0–2·5 ·· ·· ·· ·· 0·82 
(0·73–0·92)
0·85 
(0·75–0·95)
·· ··
>2·5–3·0 ·· ·· ·· ·· 0·87 
(0·76–1·00)
0·85 
(0·74–0·98)
·· ··
>3·0–3·5 ·· ·· ·· ·· 0·84 
(0·72–0·97)
0·82 
(0·71–0·96)
·· ··
>3·5–4·0 ·· ·· ·· ·· 1·13 
(0·97–1·31)
1·10 
(0·93–1·30)
·· ··
>4·0–4·5 ·· ·· ·· ·· 0·99 
(0·84–1·16)
0·93 
(0·78–1·10)
·· ··
>4·5–5·0 ·· ·· ·· ·· 1·03 
(0·84–1·28)
0·90 
(0·72–1·12)
·· ··
>5·0–5·5 ·· ·· ·· ·· 1·13 
(0·91–1·42)
0·96 
(0·76–1·20)
·· ··
>5·5–6·0 ·· ·· ·· ·· 1·27 
(1·01–1·59)
1·08 
(0·84–1·39)
·· ··
>6·0–6·5 ·· ·· ·· ·· 1·18 
(0·90–1·53)
1·02 
(0·77–1·36)
·· ··
>6·5–7·0 ·· ·· ·· ·· 1·08 
(0·78–1·50)
1·07 
(0·75–1·54)
·· ··
>7·0–7·5 ·· ·· ·· ·· 1·15 
(0·69–1·90)
1·41 
(0·84–2·36)
·· ··
>7·5–8·0 ·· ·· ·· ·· 1·18 
(0·34–4·07)
1·56 
(0·44–5·52)
·· ··
Sex
Male 18 337 33 719·9 54·4 
(53·6–55·2)
1·38 
(1·28–1·48)
1·42 
(1·33–1·53)
1·16 
(1·09–1·23)
1·42 
(1·33–1·53)
1·16 
(1·09–1·23)
Female (ref) 5532 14 050·0 39·4 
(38·3–40·4)
1 1 1 1 1
Indigenous
Yes 9147 10 851·4 84·3 
(82·6–86)
2·1 
(1·98–2·23)
·· 1·36 
(1·30–1·44)
·· 1·37 
(1·30–1·44)
No (ref) 14 722 36 918·5 39·9 
(39·2–40·5)
1 ·· 1 ·· 1
Age at OAT initiation
<25 years 10 508 14 638·8 71·8 
(70·4–73·2)
2·78 
(2·54–3·02)
2·78 
(2·55–3·03)
1·68 
(1·56–1·80)
2·78 
(2·56–3·03)
1·68 
(1·56–1·80)
25–29 years 6199 12 143·6 51·0 
(49·8–52·3)
1·94 
(1·76–2·12)
1·92 
(1·75–2·10)
1·50 
(1·40–1·62)
1·92 
(1·75–2·10)
1·50 
(1·40–1·62)
(Table 2 continues on next page)
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and crimino graphic variables (table 1 [model 3]). After 
a year from OAT initiation, the protective effect of 
OAT diminished and at 2 years post­initiation, OAT 
became positively associated with the time to first charge 
(appendix p 7).
Being in prison was associated with a reduction in the 
hazard of first charge, and those who were male, 
Indigenous, younger at OAT entry, and had more charges 
before entering OAT had an increased hazard of first 
charge (table 1 [model 3]).
Figure 1 compares the unadjusted simple 30­day moving 
average charge rate between time in and out of OAT 
across all 23 869 charge­days. Up until approxi mately 
3 years after OAT initiation, people out of treat ment had 
distinctively higher charge rates than did those in OAT.
In the unadjusted Andersen­Gill models, being in OAT 
was associated with an initial benefit in reducing overall 
charge­days, but this effect was not consistent over time 
and the HR was not proportional over the entire follow­up 
period (table 2 [model 1]). Two approaches to overcome this 
Number of 
charges
Person-years Charges per 
100 person-years 
(95% CI)
6-month step-function for OAT Continuous time-dependent 
coefficient for OAT
Model 1 Model 2 Model 3 Model 4 Model 5
(Continued from previous page)
30–34 years 3775 8366·8 45·1 
(43·7–46·6)
1·71 
(1·54–1·90)
1·70 
(1·53–1·89)
1·39 
(1·28–1·50)
1·70 
(1·53–1·89)
1·39 
(1·28–1·50)
≥35 years (ref) 3387 12 620·7 26·8 
(25·9–27·7)
1 1 1 1 1
Year of OAT initiation
2004–05 (ref) 12 028 23 749·2 50·6 
(49·7–51·6)
1 ·· 1 ·· 1
2006–07 6604 12 678·3 52·1 
(50·8–53·3)
0·88 
(0·82–0·95)
·· 0·91 
(0·87–0·96)
·· 0·91 
(0·87–0·96)
2008–09 4249 8783·9 48·4 
(46·9–49·8)
0·72 
(0·66–0·78)
·· 0·79 
(0·75–0·84)
·· 0·79 
(0·75–0·84)
2010–11 988 2558·5 38·6 
(36·2–41·0)
0·51 
(0·45–0·57)
·· 0·58 
(0·52–0·64)
·· 0·58 
(0·52–0·64)
Number of charges in the 4 years  before OAT initiation
0 (ref) 3931 18 827·9 20·9 
(20·2–21·5)
1 ·· 1 ·· 1
1–4 6023 12 690·4 47·5 
(46·3–48·7)
2·27 
(2·07–2·50)
·· 1·82 
(1·67–1·98)
·· 1·82 
(1·67–1·99)
5–14 8808 11 516·0 76·5 
(74·9–78·1)
3·66 
(3·36–3·99)
·· 2·33 
(2·13–2·55)
·· 2·33 
(2·13–2·55)
≥15 5107 4735·7 107·8 
(104·9–110·8)
5·16 
(4·70–5·66)
·· 2·57 
(2·28–2·88)
·· 2·57 
(2·28–2·89)
Number of charges since OAT 
initiation*
23 869 47 770·0 50·0 
(49·3–50·6)
1·15 
(1·14–1·17)
·· 1·14 
(1·12–1·16)
·· 1·14 
(1·12–1·16)
In prison*
Yes 2647 6129·6 43·2 
(41·5–44·8)
0·80 
(0·76–0·85)
·· 0·32 
(0·29–0·34)
·· 0·32 
(0·30–0·34)
No (ref) 21 222 41 640·3 51·0 
(50·3–51·7)
1 ·· 1 ·· 1
Number of prison episodes in the 4 years before OAT initiation
0 (ref) 9871 30 205·2 32·7 
(32·0–33·3)
1 ·· 1 ·· 1
1–5 3750 6403·8 58·6 
(56·7–60·4)
1·79 
(1·64–1·95)
·· 1·12 
(1·02–1·24)
·· 1·12 
(1·02–1·24)
6–10 5033 6392·8 78·7 
(76·6–80·9)
2·40 
(2·22–2·58)
·· 1·36 
(1·27–1·47)
·· 1·37 
(1·27–1·47)
≥11 5215 4768·1 109·4 
(106·4–112·3)
3·36 
(3·13–3·62)
·· 1·60 
(1·46–1·75)
·· 1·60 
(1·46–1·75)
−2 log likelihood ·· ·· ·· ·· 424 362·35 407 881·40 424 401·01 407 903·85
Data include 10 744 people and 23 869 charge-days. Results from Anderson-Gill intensity models. OAT initiation refers to first entry into OAT. OAT=opioid agonist treatment. NA=not applicable. 
*Time-dependent variable. Model 1 used bivariate models. Model 2 included age, sex, treatment, and a step-function for OAT. Model 3 further adjusted for all sociodemographic characteristics. Model 4 included 
age, sex, treatment, and a continuous time-dependent coefficient for OAT. Model 5 further adjusted for all sociodemographic characteristics.
Table 2: Associations between time spent in OAT and overall charge rates
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non­proportionality were assessed: modelling time in OAT 
as half­year step­functions (table 2, models 2 and 3) and as 
a continuous time­dependent coefficient by including an 
interaction term with the natural logarithm of (time 
[table 2, models 4 and 5]).
In the unadjusted step­function model and continuous 
time­dependent coefficient model, OAT was associated 
with an initial reduction in charge­days that decreased 
with time since first OAT entry. Once adjusting for 
sociodemographic and criminographic variables, the 
step­function model showed that OAT was associated 
with an initial reduction in charge­days during the 
first half­year of OAT entry, with this effect gradually 
decreasing as time since first OAT entry increased 
(table 2 [model 3], appendix p 8). This effect was no longer 
significant approximately 3 years after OAT initiation 
(table 2 [model 3], appendix p 8).
Similarly, in the adjusted continuous time­dependent 
coefficient model, OAT was associated with fewer charge­
days, although the strength of this effect decreased over 
time to the point of no benefit around 5·5 years following 
OAT initiation (table 2 [model 5], appendix p 8).
Being in prison was associated with fewer charge­days 
in the continuous time­dependent coefficient model 
(table 2 [model 5]). Conversely, being male, Indigenous, 
younger at first OAT entry, and an increase in the number 
of charges before OAT entry were all associated with an 
increased number of charge­days (table 2 [model 5]).
Figure 2 shows a continuous heat map comparing the 
unadjusted charge rates (per 100 person­years) during 
periods in and out of OAT, by the number of OAT 
episodes during follow­up and proportion of follow­up 
time spent in OAT. Charge rates and the quartile cutoff 
points used to define each of the follow­up groups are 
provided in the appendix (pp 9, 10). Overall, compared 
with charge rates out of OAT, charge rates while in OAT 
were generally lower among people with fewer OAT 
episodes and those who spent a greater proportion of 
follow­up time in OAT (figure 2).
The results of the adjusted zero­inflated negative 
binomial model support this finding. The overall charge 
rate increased as the number of OAT episodes increased 
and when relatively lower proportions of time were spent 
in OAT (table 3). There were no notable differences in 
the effect sizes produced by any of the models in the 
sensitivity analyses (appendix pp 11–13).
Discussion
Reflecting the dynamic and cyclical nature of OAT in 
clinical practice, our study undertook a comprehensive 
and unique examination of the potential effect of OAT on 
charge rates, considering various time periods within 
an OAT episode and varying patterns of engagement in 
OAT across treatment episodes and episode lengths. In 
addition to reinforcing the notion that a complex relation­
ship exists between opioid dependence, OAT, and contact 
with the criminal justice system, our findings also provide 
Figure 2: Continuous heat map of unadjusted charge rate for individuals in and out of OAT
The heat map summarises the relative intensity of charge rates by different profiles of OAT engagement, focusing 
on two features: number of OAT episodes and proportion of follow-up time in OAT. The relative intensity of the 
charge rates is displayed in colour scale ranging from green (lowest charge rates) to yellow, orange, and red 
(highest charge rates). Profiles of treatment engagement associated with lower charge rates are represented by 
areas with a greater intensity of green, and those associated with higher charge rates are represented by areas with 
a greater intensity of red. Thresholds used to define lowest, low-mid, high-mid, and highest groups are based on 
the quartile cutoffs for the proportion of follow-up time spent in OAT among people with the same number of 
treatment episodes (appendix p 10). OAT=opioid agonist treatment.
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Lowest Low-mid High-mid Highest
Proportion of follow-up time in OAT
In OAT Out of OAT
100
Charge rate (per 
100 person-years)
200
300
No charges during 
follow-up (OR [95% CI])
Number of charges during 
follow-up (IRR [95% CI])
Number of OAT episodes 0·44* (0·38–0·50) 1·13* (1·11–1·15)
Proportion of follow-up time spent in OAT
Lowest 1·11 (0·88–1·40) 1·11* (1·02–1·21)
Low-mid 0·77* (0·60–1·00) 1·18* (1·08–1·28)
High-mid 0·78* (0·61–1·00) 1·22* (1·12–1·33)
Highest (ref) 1 1
Percent of days in OAT spent in prison 1·10* (1·05–1·14) 0·98* (0·96–0·99)
Percent of follow-up time spent in prison 1·02 (0·96–1·10) 1·15* (1·13–1·18)
Sex
Male 0·61* (0·51–0·70) 0·98 (0·92–1·05)
Female (ref) 1 1
Indigenous
Yes 0·46* (0·36–0·60) 1·15* (1·07–1·23)
No (ref) 1 1
Age at OAT initiation
<25 years 0·53* (0·42–0·68) 1·36* (1·25–1·48)
25–29 years 0·72* (0·58–0·89) 1·27* (1·16–1·39)
30–34 years 0·70* (0·54–0·89) 1·21* (1·10–1·33)
≥35 years (ref) 1 1
Any charge in the 4 years before OAT initiation
No 7·92* (6·24–10·10) NA
Yes (ref) 1 NA
Number of charges in the 4 years before OAT initiation
None (ref) NA 1
1–4 NA 1·18* (1·09–1·29)
5–14 NA 1·64* (1·50–1·78)
≥15 NA 1·92* (1·72–2·14)
Results are from zero-inflated negative binomial model. OAT initiation refers to first entry into OAT. OR=odds ratio. 
IRR=incident rate ratio. OAT=opioid agonist treatment. NA=not applicable. *Significant at the 0·05 level, two-sided 
test.
Table 3: Associations between number of OAT episodes and time spent in OAT and number of charges 
during follow-up
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several novel and important insights regarding the 
effectiveness of OAT in reducing charge rates.
OAT was associated with an initial benefit in delaying 
the time to first charge and reducing the overall number 
of charge­days; however, this protective effect decreased 
over time. Although findings from randomised controlled 
trials have shown mixed findings with regards to the 
benefit of OAT on crime,14–16 most observational studies 
have identified that OAT, either directly or indirectly, is 
associated with some degree of crime reduction.17,19–21 
Notwithstanding the methodological differences across 
observational studies, various system­level factors also 
play an important role in the nature and extent to which 
OAT reduces contact with the criminal justice system, 
particularly in regards to thresholds for programme entry. 
For example, although NSW had no specific eligibility 
criteria to enter the OAT programme other than opioid 
dependence, the timing of the reductions in crime 
observed in Norway can be attributed to the strict entrance 
requirements for the programme (eg, participants had to 
be aged ≥25 years, dependent on heroin for several years, 
and have undergone previous abstinence­oriented treat­
ment), resulting in participants being more motivated to 
cease offending before commencing OAT.17
People in OAT commonly cycle in and out of treatment 
and our findings identified a clear relationship between 
the nature and extent of engagement in OAT and overall 
charge rates, in and out of OAT. Those who spent a greater 
proportion of their follow­up time in treatment, and with 
fewer separate episodes of treatment, had the lowest rates 
of charges both in and out of OAT. By contrast, during 
periods in OAT, charge rates were generally higher among 
people with more treatment episodes even if a greater 
amount of their follow­up time was spent in treatment. 
Hence, offending is not simply influenced by the total 
amount of time spent in OAT, but also by continuous time 
spent in OAT. This finding is supported by studies in the 
UK19 and Norway,18 whereby the greatest crime reductions 
were observed during periods of continuous treatment.
The characteristics and long­term goals of OAT are 
often debated29 and, overall, our findings provide further 
evi dence that increased retention in OAT is associated 
with notably improved treatment outcomes. To date, 
much of the evidence supporting the need for treatment 
retention has focused on health outcomes (eg, mortality);2 
however, our study identified that these benefits also 
extend to other domains—namely, contact with the 
criminal justice system. The provision of OAT with oral 
or buccal formulations of methadone and buprenorphine 
is the gold standard treatment approach for opioid depen­
dence but there is ongoing interest in investigating 
methods and approaches to promote improved adherence 
and reduced cycling in and out of OAT. For example, 
clinical trials of long­acting bupre norphine depot formu­
la tions have shown promising results and might pro­
vide alternative treatment options to assist in improved 
adherence in the future.30
Importantly, almost half of the cohort had no charges 
during an extended period of follow­up. Offending is often 
not solely influenced by opioid or other drug use and 
evidence exists that the onset of offending often occurs 
before the onset of opioid use (although opioid use does 
appear to increase intensity of offending).6 Therefore, drug 
treatment and concomitant reductions in illicit opioid use 
might not directly affect the offending patterns of some 
individuals, which might in part also explain the reduction 
in the protective effect of OAT that was observed in our 
study for some of the outcome measures. The reasons 
motivating an individual to offend are multifactorial and 
although OAT provides many important health benefits 
for those with opioid dependence, pharmacotherapy alone 
is unlikely to address the broader social issues that 
influence offending for all individuals and many will 
require additional support. Hence, addressing other 
factors associated with offending, including poverty, social 
network norms, and criminogenic needs, might also be 
necessary to ensure stable reductions in offending.
A key strength of this study was the use of linked 
administrative datasets to examine the long­term effective­
ness of OAT on charge rates among a population­based 
cohort of new OAT entrants, and for the first time, 
accounting for time in prison. All individuals who receive 
OAT in NSW must be formally registered at the time of 
entry into treatment and evidence exists that most indi­
viduals who develop opioid dependence engage in OAT 
services at some point in time. Consequently, our findings 
are likely to be highly representative of people who are 
opioid dependent in NSW. However, the findings might 
not be representative of individuals who receive OAT in 
other jurisdictions across Australia. Although the use 
of administrative data enabled us to assess treatment, 
incarceration, and charges on a day­by­day basis and con­
trol for several potential confounders, dose infor mation 
was not available and individual­level factors motivating 
entry or influencing the extent of OAT engagement could 
not be accounted for and warrant further investigation. 
Given that not all offences are reported to police, the true 
rates of offending are likely to have been underestimated. 
It is also possible that some people were convicted 
of offences that they did not commit and that some 
offences were overturned upon successful appeal, which 
would not have been captured in our data. However, no 
evidence exists to suggest that these events are more 
likely to occur among opioid­dependent people in or 
out of OAT and are therefore not expected to affect our 
results.
Our findings collectively show that OAT is associated 
with a significant reduction in charge rates and is most 
protective with increased treatment engagement. Further­
more, engaging in OAT on a continuous basis appears to 
be most beneficial in reducing overall charge rates. An 
increased focus on encouraging retention in OAT is 
therefore necessary to maximise the long­term health and 
social benefits of OAT.
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